Aurinia Pharmaceuticals Inc (AUPH) Gets the Thumbs Up From Cantor

Published on April 10, 2017 at 7:44 pm by Insider Monkey Team in News

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is in the spotlight on Monday after Cantor Fitzgerald initiated an ‘Overweight’ rating and a target of $14 per share. Cantor analyst Elemer Piros is bullish on the name due to his belief that Aurinia’s lead drug candidate, voclosporin, has shown ‘compelling efficacy’ (in his view) in the Phase 2 study, AURA-LV. Dr. Piros believes the commercial market opportunity could be as much as $1.6 billion in just the United States.

After surging sharply in early March, volatility surrounding Aurinia has inched lower as traders have digested much of the present news. Some traders believe shares of the Aurinia could be in focus later on this month, when the company hosts an Investor Event during the National Kidney Foundation Spring Clinical Meeting on April 20, 2017 at 6:00pm Eastern Time. The event is intended for sell-side analysts, investors, and business development professionals.

What Does The Smart Money Sentiment Say?

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

Given that it’s a small company, none of the 742 elite funds in our database owned Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) at the end of Q4. That metric might change going forward, however.

The Bottom Line

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are in the spotlight today after Cantor Fitzgerald gave the thumbs up to the stock. For more reading, check out ‘11 Biggest Generic Drug Companies In the World‘.